146 related articles for article (PubMed ID: 9949292)
21. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential.
Haas CJ; Diebold J; Hirschmann A; Rohrbach H; Löhrs U
Virchows Arch; 1999 Feb; 434(2):117-20. PubMed ID: 10071245
[TBL] [Abstract][Full Text] [Related]
22. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
23. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
[TBL] [Abstract][Full Text] [Related]
24. Relationships between c-Ki-ras mutations, HPV types, and prognostic indicators in invasive endocervical adenocarcinomas.
Koulos JP; Wright TC; Mitchell MF; Silva E; Atkinson EN; Richart RM
Gynecol Oncol; 1993 Mar; 48(3):364-9. PubMed ID: 8385060
[TBL] [Abstract][Full Text] [Related]
25. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
26. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas.
Suzuki M; Saito S; Saga Y; Ohwada M; Sato I
Cancer Genet Cytogenet; 2000 Apr; 118(2):132-5. PubMed ID: 10748293
[TBL] [Abstract][Full Text] [Related]
27. [K-ras gene mutation in gallbladder carcinoma].
Roa JC; Roa I; de Aretxabala X; Melo A; Faría G; Tapia O
Rev Med Chil; 2004 Aug; 132(8):955-60. PubMed ID: 15478297
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas.
Z'graggen K; Rivera JA; Compton CC; Pins M; Werner J; Fernández-del Castillo C; Rattner DW; Lewandrowski KB; Rustgi AK; Warshaw AL
Ann Surg; 1997 Oct; 226(4):491-8; discussion 498-500. PubMed ID: 9351717
[TBL] [Abstract][Full Text] [Related]
29. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
30. The balanced induction of K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues.
Kraus MC; Seelig MH; Linnemann U; Berger MR
Int J Oncol; 2006 Oct; 29(4):957-64. PubMed ID: 16964391
[TBL] [Abstract][Full Text] [Related]
31. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
[TBL] [Abstract][Full Text] [Related]
32. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis.
Mills NE; Fishman CL; Scholes J; Anderson SE; Rom WN; Jacobson DR
J Natl Cancer Inst; 1995 Jul; 87(14):1056-60. PubMed ID: 7616596
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection.
Takeshima Y; Amatya VJ; Daimaru Y; Nakayori F; Nakano T; Inai K
Hum Pathol; 2001 Nov; 32(11):1203-8. PubMed ID: 11727259
[TBL] [Abstract][Full Text] [Related]
34. K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
Alvarez AA; Moore WF; Robboy SJ; Bentley RC; Gumbs C; Futreal PA; Berchuck A
Gynecol Oncol; 2001 Feb; 80(2):201-6. PubMed ID: 11161860
[TBL] [Abstract][Full Text] [Related]
35. K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
Enomoto T; Inoue M; Perantoni AO; Buzard GS; Miki H; Tanizawa O; Rice JM
Cancer Res; 1991 Oct; 51(19):5308-14. PubMed ID: 1913654
[TBL] [Abstract][Full Text] [Related]
36. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.
Lavarino C; Pilotti S; Oggionni M; Gatti L; Perego P; Bresciani G; Pierotti MA; Scambia G; Ferrandina G; Fagotti A; Mangioni C; Lucchini V; Vecchione F; Bolis G; Scarfone G; Zunino F
J Clin Oncol; 2000 Dec; 18(23):3936-45. PubMed ID: 11099323
[TBL] [Abstract][Full Text] [Related]
37. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
38. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
Kolasa IK; Rembiszewska A; Janiec-Jankowska A; Dansonka-Mieszkowska A; Lewandowska AM; Konopka B; Kupryjańczyk J
Gynecol Oncol; 2006 Nov; 103(2):692-7. PubMed ID: 16793127
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium.
Manavi M; Bauer M; Baghestanian M; Berger A; Kucera E; Pischinger K; Battistutti W; Czerwenka K
Tumour Biol; 2001; 22(5):299-309. PubMed ID: 11553860
[TBL] [Abstract][Full Text] [Related]
40. Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision?
Desouki MM; Khabele D; Crispens MA; Fadare O
Int J Gynecol Pathol; 2015 Jan; 34(1):19-24. PubMed ID: 25473748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
